Humira Competitors Don’t Guarantee Lower Patient Drug Costs
Celine Castronuovo | Bloomberg Law News
“The launches this month are “more of an inflection point in the market compared to what we saw in January when Amjevita came to market,” said Alex Brill, founder and CEO of economic policy consulting firm Matrix Global Advisors, referring to Amgen Inc.’s product that became the first Humira biosimilar earlier this year.
“A preferred positioning on the formulary would help them more than parity that they’re getting.'”
Read the full article here. Additional commentary can be found here.
